{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:17:08Z","timestamp":1785799028918,"version":"3.56.0"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Innovative Medicine Program of Chinese Academy of Medical Sciences","award":["2017-I2M-1-002"],"award-info":[{"award-number":["2017-I2M-1-002"]}]},{"name":"National Clinical Research Program for Obstetric & Gynecologic Diseases","award":["FL2021"],"award-info":[{"award-number":["FL2021"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To validate the colposcopy indication proposed by the 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests (the 2019 ASCCP guidelines).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Clinical data of 1404 patients who underwent colposcopy in single center in China were reviewed. Based on history and current cervical screening (HPV &amp; cytology), corresponding recommendations were given according to the 2019 ASCCP guidelines. The agreement and discrepancy of colposcopy indication were analyzed between the Chinese consensus and the 2019 ASCCP guidelines.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Colposcopy indication was matched in about 80% patients. The left 20% were recommended with follow-up by the 2019 ASCCP guidelines. The discrepancy mainly focused on patients having a current result of HPV-positive NILM without unknown history. The ratio of observed CIN3+ in our database over estimated CIN3+ by the 2019 ASCCP guidelines was 6.2 (31\/5). The ratio was even higher in patients with HPV16\/18-positive NILM (7, 28\/4), compared with those with other types of high-risk HPV-positive NILM (3, 3\/1). The 2019 ASCCP guidelines had a relatively high sensitivity (83.1%), a low specificity (21.5%), a low positive predictive value (14.1%) and a high negative predictive value (89.1%) for prediction of CIN 3+.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>We could try to apply the 2019 ASCCP guidelines in Chinese population. The classification of HR-HPV was strongly recommended during risk assessment. For patients with HPV16\/18 infection, colposcopy should be recommended. Perspective multi-center randomized controlled trial with reliable follow-up should be performed in the future to confirm the feasibility.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0253493","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T17:47:39Z","timestamp":1625161659000},"page":"e0253493","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Validation of the indication for colposcopy proposed by the 2019 ASCCP risk-based management consensus guidelines: A single-center study in China"],"prefix":"10.1371","volume":"16","author":[{"given":"Ting","family":"Gui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-2571","authenticated-orcid":true,"given":"Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"pone.0253493.ref001","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00128360-200204000-00012","article-title":"2001 consensus guidelines for the management of women with cervical cytological abnormalities","volume":"6","author":"TC Wright","year":"2002","journal-title":"J Low Genit Tract Dis"},{"key":"pone.0253493.ref002","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ajog.2007.07.047","article-title":"2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests","volume":"197","author":"TC Wright","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"pone.0253493.ref003","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/AOG.0b013e3182883a34","article-title":"2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors","volume":"121","author":"LS Massad","year":"2013","journal-title":"Obstet Gynecol"},{"key":"pone.0253493.ref004","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"RB Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"pone.0253493.ref005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3322\/caac.21139","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer","volume":"62","author":"D Saslow","year":"2012","journal-title":"CA Cancer J Clin."},{"key":"pone.0253493.ref006","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/LGT.0000000000000529","article-title":"Risk estimates supporting the 2019 ASCCP risk-based management consensus guidelines","volume":"24","author":"D Egemen","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"pone.0253493.ref007","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/LGT.0000000000000528","article-title":"A 2019 ASCCP risk-based management consensus guidelines: methods for risk estimation, recommended management, and validation","volume":"24","author":"LC Cheung","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"pone.0253493.ref008","doi-asserted-by":"crossref","first-page":"946","DOI":"10.5858\/2003-127-946-FTDFTA","article-title":"Finding to date from the ASCUS-LSIL triage study (ALTS)","volume":"127","author":"M Schiffman","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"pone.0253493.ref009","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","article-title":"Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test","volume":"136","author":"TC Wright","year":"2015","journal-title":"Gynecol Oncol"},{"key":"pone.0253493.ref010","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1309\/AJCPZ5JY6FCVNMOT","article-title":"High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study","volume":"135","author":"MH Stoler","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"pone.0253493.ref011","first-page":"CD008054","article-title":"Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions","volume":"3","author":"M Arbyn","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0253493.ref012","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/pgp.0b013e31805152ab","article-title":"CIN 2 is a much less reproducible and less valid diagnosis than CIN 3: results from a histological review of population-based cervical samples.","volume":"26","author":"JD Carreon","year":"2007","journal-title":"Int J Gynecol Pathol"},{"key":"pone.0253493.ref013","doi-asserted-by":"crossref","first-page":"8578","DOI":"10.1158\/0008-5472.CAN-10-1188","article-title":"Hierarchical clustering of human papillomavirus genotype patterns in the ASCUS-LSIL triage study","volume":"70","author":"N Wentzensen","year":"2010","journal-title":"Cancer Res"},{"key":"pone.0253493.ref014","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/1940-6207.CAPR-17-0293","article-title":"Clinical outcomes after conservative management of cervical intraepithelial neoplasia grade 2 (CIN 2) in women ages 21\u201339 years","volume":"11","author":"MI Silver","year":"2018","journal-title":"Cancer Prev Res (Phila)"},{"key":"pone.0253493.ref015","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/AOG.0b013e3181fe777f","article-title":"Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women","volume":"116","author":"AB Moscicki","year":"2010","journal-title":"Obstet Gynecol"},{"key":"pone.0253493.ref016","doi-asserted-by":"crossref","first-page":"k499","DOI":"10.1136\/bmj.k499","article-title":"Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis","volume":"360","author":"K Tainio","year":"2018","journal-title":"BMJ"},{"key":"pone.0253493.ref017","doi-asserted-by":"crossref","first-page":"46. e1","DOI":"10.1016\/j.ajog.2011.07.024","article-title":"The ATHENA human papillomavirus study: design, methods, and baseline results.","volume":"206","author":"TC Wright","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"pone.0253493.ref018","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ygyno.2018.04.007","article-title":"The onclarity human papillomavirus trial: design, methods, and baseline results","volume":"149","author":"MH Stoler","year":"2018","journal-title":"Gynecol Oncol"},{"key":"pone.0253493.ref019","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1309\/AJCPSD3ZXJXP7NNB","article-title":"Cervical histopathology variability among laboratories: a population-based statewide investigation","volume":"139","author":"JC Gage","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"pone.0253493.ref020","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/ijc.27608","article-title":"A population-based study of human papillomavirus genetype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination","volume":"132","author":"CM Wheeler","year":"2013","journal-title":"Int J Cancer"},{"key":"pone.0253493.ref021","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.amepre.2014.05.016","article-title":"Impact of the National Breast and Cervical Cancer Early Detection Program on cervical cancer mortality among uninsured low-income women in the U.S., 1991\u20132007","volume":"47","author":"DU Ekwueme","year":"2014","journal-title":"Am J Prev Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0253493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T17:47:59Z","timestamp":1625161679000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0253493"}},"subtitle":[],"editor":[{"given":"Zhi-Ming","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0253493","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]}}}